Patent & IP news for March 8, 2015

Those EPO management criticisms: the Central Staff Committee responds from ipkitten.blogspot.com

Merpel posted last week an open letter in which the management of the European Patent Office criticised staff representatives for their behaviour in the meeting that was supposed to discuss reform to the sick leave ...

Share via E–mail | Twitter | Facebook

Offering a service is not use in commerce Under Lanham Act, says Federal Circuit Court from ipkitten.blogspot.com

The case that forms the subject of this guest blog from Katfriend, blogger and recent guest Kat Marie-Andrée Weiss is one that immediately caught the IPKat's attention since his first thought was to ask ...

Share via E–mail | Twitter | Facebook

IP in Luxury Goods and Fashion: a patent Kat investigates from ipkitten.blogspot.com

This Kat had a great time at ialci’s recent conference on ‘Intellectual Property: how to protect, manage and & monetise the know-how, intangible capital, brand image and reputation of luxury maisons & fashion brands’. Coming from ...

Share via E–mail | Twitter | Facebook

The IPKat weblog and the European Patent Office: some points of clarification from ipkitten.blogspot.com

This moggy notes with concern that the posting of comments on the IPKat's weblog on European Patent Office (EPO) matters has got somewhat out of hand. The IPKat has asked her to have a ...

Share via E–mail | Twitter | Facebook

Why Women Entrepreneurs are the Future of Tech from www.iposgoode.ca

The world has many problems to solve. Billions live without reliable energy and lack adequate access to water, healthcare, and education. More people die from lack of clean water than from war. Our food system ...

Share via E–mail | Twitter | Facebook

Universities dealing with student copyright infringers from ipbiz.blogspot.com

From USAToday:

--
Under the DMCA, universities like Columbia are required to deal with each report of infringement in an “expedient” manner, which includes terminating Internet service for repeat offenders. Stanford University termites the Internet access ...

Share via E–mail | Twitter | Facebook

In TPP, USTR Seeks To Boost Criminal Remedies Against IP Infringement from www.ip-watch.org

United States trade negotiators are seeking to set a "new regional standard" against intellectual property infringement in the Pacific region with the Trans-Pacific Partnership (TPP) agreement. And among the new tools it is seeking is ...

Share via E–mail | Twitter | Facebook

"60 Minutes" on March 8, 2015 from ipbiz.blogspot.com

Lesley Stahl on the death of the Argentine prosecutor, Alberto Niesmann.  Alberto had ten bodyguards, but did not trust them.  A forensic team ruled the death a murder.
Alberto was named a special prosecutor in ...

Share via E–mail | Twitter | Facebook

Syruptitious episode of Battle Creek does counterfeit products from ipbiz.blogspot.com

"Battle  Creek" gets into maple syrup in the "Syruptitious" episode.  Meredith Eaton appears as a diminutive medical examiner (as done in NCIS)  and finds that the corpse drowned in maple syrup.

There is a sub-plot ...

Share via E–mail | Twitter | Facebook

EPO human rights issues and EU patent (litigation) reform: questions and concerns from www.fosspatents.com

Before the European patent system can grow in terms of having an EU unitary patent and a European Unified Patent Court (UPC), it may have to improve in some fundamental respects. Of course, improvements could ...

Share via E–mail | Twitter | Facebook

Conference & CLE Calendar from www.patentdocs.org

March 10, 2015 - 25th Annual Conference on USPTO Law and Practice (PTO Day) (Intellectual Property Owners Association & U.S. Patent and Trademark Office) - Washington, D.C. March 10-11, 2015 - FDA Boot Camp*** (American Conference Institute ...

Share via E–mail | Twitter | Facebook

FDA Approves Sandoz Filgrastim Biosimilar from www.patentdocs.org

By Kevin E. Noonan -- On Friday, the Food and Drug Administration approved a biosimilar version of Amgen's Neupogen® (filgrastim) product for sale in the U.S. This is the first biosimilar to be approved ...

Share via E–mail | Twitter | Facebook